Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Sales Reps in Japan Decrease to 57,158 in FY2019, Down for 6 Years Running: Survey
November 5, 2020
- PhRMA Makes 3-Pronged Proposal to Japan Govt, Calls for Fueling Innovation, Investment, and Digitalization
October 29, 2020
- Japan Trade Groups Step Up Lobbying Campaigns as Diet Convenes, Renew Call for “Cautious Approach” to Off-Year Re-Pricing
October 27, 2020
- FPMAJ Urges Drug Makers to Ensure Stable Supply of Newly Listed Products
October 16, 2020
- COVID-19 Affecting Reimbursement Fee Incentive for Biosimilars: JPA Exec
October 16, 2020
- Take COVID as Opportunity to “Reset” Overdependence on Drug Price Cuts: PhRMA Chief
October 12, 2020
- Don’t Politicize Coronavirus Vaccine Introduction: Drug Damage Watchdog
October 8, 2020
- Ex-MHLW Official Takeyuki Sato Named JGA Director General
October 2, 2020
- Coronavirus Vaccines Must Be Offered to All Humanity: EFPIA Japan Webinar
October 1, 2020
- Generic Use Rate at 79.3% in April-June, Just Shy of Govt Target: JGA
October 1, 2020
- EFPIA Global, Japan Chiefs Call for Appropriate Reward for Innovation
September 30, 2020
- New Cabinet Well Organized, Full of People with Practical Experience: JPMA Director General
September 23, 2020
- Drug Wholesalers’ Sales Up 2.54%, Improving Profit Rates in FY2019: JPWA
September 23, 2020
- Ex-MHLW Councilor Mori to Become JPMA’s Sr. Managing Director in October
September 18, 2020
- Japan Pharma Groups Stepping Up Lobbying on FY2021 Budget, Tax Reform
September 17, 2020
- JPMA Policy Proposal Calls for Govt’s Flexibility towards Coronavirus Vaccinations, Steps to Expedite Visas for Foreign Technicians
September 15, 2020
- EFPIA Japan Issues Statement on Vaccination System under COVID-19 Crisis, Calls for Eliminating Obstacles for Vaccine Imports
September 14, 2020
- JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
September 7, 2020
- Generic APIs at Crossroads - 2: Traders’ Group Urges Simpler Regulatory Procedures to Facilitate API Substitution
August 13, 2020
- JMA’s New Pharma Affairs Exec Wants More Stringent Rules on Sakigake, Conditional Approval
August 11, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…